EUVIMEDEUVIMED entdecken
Crossref

Oncolyitic Virus Therapy: A Review

Covid Research and Treatment · 2026

DOI: 10.58489/2836-3604/020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Covid Research and Treatment, 2026.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Oncolytic viruses (OVs) have emerged as promising therapeutic agents for the treatment of malignant tumors due to their ability to selectively infect and lyse cancer cells while sparing normal tissues. In addition to their direct oncolytic activity, OVs stimulate both innate and adaptive antitumor immune responses, making them an attractive platform for targeted cancer therapy. The therapeutic efficacy of OVs depends primarily on their tumor selectivity and their capacity to enhance tumor cell destruction through multiple mechanisms. Advances in molecular biotechnology and genetic engineering have enabled the modification of wild-type viral strains to improve tumor specificity, increase therapeutic potency, reduce toxicity, and enhance safety profiles, thereby facilitating their evaluation in clinical trials. This review provides a comprehensive overview of oncolytic virotherapy, including its mechanisms of action, clinical applications, combination treatment strategies, current challenges, and future prospects. Moreover, combining OVs with conventional therapies such as chemotherapy, radiotherapy, immune checkpoint inhibitors, and targeted therapies has shown synergistic antitumor effects and enhanced therapeutic efficacy. Certain oncolytic viruses are also capable of inducing durable antitumor immune memory, thereby reducing the risk of tumor recurrence and metastasis. Despite these advances, the clinical translation of oncolytic virotherapy in veterinary medicine remains limited. Although promising results have been obtained in preclinical studies, further research is required to establish its safety, efficacy, and practical application in veterinary oncology. One of the major obstacles to successful virotherapy is the efficient and targeted delivery of viruses to tumor sites. Systemic administration is often hindered by pre-existing antiviral immunity, rapid viral clearance, and limited tumor penetration, whereas intratumoral administration is invasive, technically challenging, and costy. Consequently, the development of effective viral delivery systems capable of overcoming these barriers remains a critical research priority. Continued advances in viral engineering, immunotherapy, and targeted delivery technologies are expected to accelerate the clinical translation of oncolytic virotherapy, making it an increasingly important component of future cancer treatment strategies in both human and veterinary medicine.

Zitieren

APA

(2026). Oncolyitic Virus Therapy: A Review. Covid Research and Treatment. https://doi.org/10.58489/2836-3604/020

Vancouver

Oncolyitic Virus Therapy: A Review. Covid Research and Treatment. 2026. doi:10.58489/2836-3604/020

BibTeX
@article{euvimed2026,
  title = {Oncolyitic Virus Therapy: A Review},
  journal = {Covid Research and Treatment},
  year = {2026},
  doi = {10.58489/2836-3604/020}
}
Kostenlos starten →